Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...

在2025年ASCO泌尿生殖系统肿瘤研讨会上，研究人员针对晚期肾细胞癌（RCC）和转移性去势抵抗性前列腺癌（mCRPC）的耐药难题，公布了HIF-2α抑制剂Belzutifan联合疗法及EZH2抑制剂Mevrometostat的突破性成果。LITESPARK-005研究证实Belzutifan单药显著延长PFS，而KEYMAKER-U03B平台 ...

As a Keymaker, we know that there isn’t a skeleton key that fits every person. And because of that we work hard to design the support & programing that you, your youth & family needs. That means if ...

As a Keymaker, we know that there isn’t a skeleton key that fits every person. And because of that we work hard to design the support & programing that you, your youth & family needs. That means if ...